# Caplin Point Laboratories Ltd (CAPLIPOINT)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹2025.9
Day Change: +0.46%
52W High: ₹2395
52W Low: ₹1500.3
Market Cap: ₹15,116 Cr

## Valuation
P/E: 23.63
P/B: 4.9
EPS: ₹84.15
Book Value: ₹405.84
Dividend Yield: 0%

## Returns
1Y Return: 2.57%

## Profitability
ROE: 0%
ROCE: 32.5%
Debt/Equity: 0
Revenue Growth: 10.1%
Profit Growth: 18.3%
EBITDA Margin: 34.92%
Operating Margin: 31.4%

## About
Caplin Point Laboratories Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Caplin Point Laboratories Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Announcement: Announcement under Regulation 30 (LODR)-Press Release / Media Release
- BSE Filing: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

## Access
Current tier: anonymous
More history: Register free to see 8 more years.

## Data Freshness
Quote Updated: 2026-05-21T20:00:00.503Z
Price History Updated: 2026-05-17T21:25:10.058Z
Latest Price History Date: 2026-05-17
Technicals Updated: 2026-05-17T21:25:10.058Z
Quant Updated: 2026-05-17T21:25:10.058Z
Sentiment Updated: 2026-05-17T21:25:10.058Z
Financials Status: current
Financials Updated: 2026-05-18T09:32:01.256Z
Financials Last Attempt: 2026-05-18T09:32:01.256Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2016
            
            
              9m)
Revenue: ₹252 Cr
Operating Profit: ₹60 Cr (OPM 24%)
Net Profit: ₹41 Cr
Tax: ₹53 Cr

## Annual P&L History
Mar 2016
            
            
              9m: Rev ₹252Cr | PAT ₹41Cr | OPM 24%
Mar 2017: Rev ₹239Cr | PAT ₹46Cr | OPM 27%
Mar 2018: Rev ₹402Cr | PAT ₹96Cr | OPM 31%

## Balance Sheet (Mar 2016)
Total Assets: ₹229 Cr
Total Liabilities: ₹229 Cr
Borrowings: ₹2 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Sridhar  Ganesan, MD & Whole Time Director
- D.  Muralidharan, Chief Financial Officer - Finance & Accounts
- Venkatram Ganapathisu Bramanian, General Counsel, Company Secretary & Compliance Officer
- Neelakandan  K., President - API R&D - Hyderabad
- Anto Vijinth V., Functional Head -HO, HR & Admin

---
Source: rupiya.io/stocks/caplipoint
Disclaimer: For research and education only. Not investment advice.